Summary
Emerging disease risks in the United States and globally have risen amid significant cuts to public health programs during the Trump administration. These reductions targeted key agencies such as the Centers for Disease Control and Prevention (CDC) and the United States Agency for International Development (USAID), leading to diminished capacity for infectious disease surveillance, outbreak response, and global health security efforts. The administration’s policy shifts involved deep funding and staffing cuts, organizational restructurings, and a narrowed focus on surveillance and containment primarily of diseases originating outside the U.S., raising concerns about weakened preparedness for both domestic and international emerging health threats.
Notably, budget reductions severely impacted CDC programs addressing HIV, viral hepatitis, tuberculosis, and other infectious diseases, with some program funding shrinking by as much as 80%, and critical units such as the Division of Parasitic Diseases and Malaria being disbanded. These cuts coincided with outbreaks of preventable diseases, including local malaria transmission and a hantavirus outbreak that highlighted delays in official public health communication and response. At the same time, the administration’s withdrawal from the World Health Organization (WHO) and reorganization of global health programs further disrupted international disease control initiatives, eliciting warnings from experts about increased risks of unchecked epidemics and pandemics.
Public health experts and lawmakers widely criticized these changes, emphasizing that the erosion of surveillance infrastructure and diminished interagency coordination could impede early detection and rapid containment of emerging pathogens. Critics argued that these policy decisions undermined America’s role in global health leadership and increased vulnerabilities to infectious diseases amid a growing threat landscape exacerbated by climate change and global travel. Conversely, some administration officials defended the refocused priorities on chronic disease prevention and cost-effective interventions, though these positions sparked debate over balancing immediate infectious disease risks with broader health objectives.
Overall, the Trump administration’s health program cuts represent a significant departure from previous efforts to strengthen disease prevention and global health security, with lasting implications for the United States’ readiness to address emerging infectious diseases. Ongoing concerns persist regarding the ability of reduced public health infrastructure to manage future outbreaks effectively, underscoring the critical need for sustained investment in surveillance, research, and international cooperation to mitigate rising disease risks.
Background
During the Trump administration, significant cuts and shifts in funding priorities impacted U.S. public health programs focused on emerging infectious diseases and global health security. These changes included reductions in support for activities beyond health commodities and frontline health personnel, with a narrowed emphasis on surveillance, data sharing, and laboratory capacity aimed primarily at detecting and containing outbreaks originating outside the United States. Such adjustments diminished the capacity for advanced surveillance, epidemiology, and laboratory science, including metagenomic surveillance at ports of entry, which are critical for monitoring emerging health threats.
This reduction in resources affected key programs run by agencies such as the Centers for Disease Control and Prevention (CDC), which fund state, tribal, local, and territorial health departments to implement high-impact prevention efforts against HIV, viral hepatitis, sexually transmitted infections, and tuberculosis. Additionally, the scaling back of U.S. Agency for International Development (USAID) Global Health Security (GHS) programs raised concerns about the potential increase in infectious disease cases globally, with an internal USAID memo warning of a risk of more than 28,000 new cases annually of diseases such as Ebola and Marburg if these programs were lost.
Experts have highlighted that these cuts and shifts in strategy could hinder communication and coordination across U.S. agencies and with international partners, potentially slowing responses to emerging health threats and increasing the risk of disease importation into the United States. Given estimates that there is a 50% chance of another pandemic emerging within the next 25 years—particularly in less prepared countries—such reduced capacity poses significant risks to global and domestic health security.
The impact of these changes was also evident in public health communication during outbreaks. For example, during a hantavirus outbreak, critical information was initially reported by media outlets rather than through official channels such as the CDC or the State Department, which was coordinating the national response. This delay in official communication highlighted challenges in timely public health reporting under the administration’s approach.
Health Program Changes During the Trump Administration
Since the beginning of President Trump’s second term, his administration implemented numerous policy actions through the Department of Health and Human Services (HHS) that significantly altered public health programs in the United States. These changes included funding reductions, staffing cuts, and organizational restructurings, particularly impacting the Centers for Disease Control and Prevention (CDC) and global health initiatives.
One of the most notable impacts was on infectious disease prevention and surveillance programs. The CDC experienced deep spending and staffing cuts that diminished its capacity to track and respond to disease outbreaks both domestically and internationally. For instance, funding for CDC programs targeting HIV, viral hepatitis, sexually transmitted infections, and tuberculosis was dramatically reduced from $1.5 billion to $300 million through consolidation efforts aimed at increasing state flexibility but raising concerns about diminished disease-specific expertise. Experts warned that reductions in staff and expertise could exacerbate public health risks, as fewer personnel were available to prevent or monitor infectious diseases.
The Trump administration also initiated a substantial reorganization of the National Institutes of Health (NIH), proposing to cut its discretionary budget by about 40% and consolidate its 27 institutes and centers into eight. This reorganization preserved only a handful of key institutes while eliminating those focused on minority health, alternative medicine, nursing, and global health research. These cuts, coupled with a proposed 15% cap on indirect costs paid to institutions receiving NIH funds, faced legal challenges but signaled a deprioritization of biomedical research critical to infectious disease control.
On the global health front, the administration’s withdrawal of the U.S. from the World Health Organization and the dismantling of the United States Agency for International Development (USAID) disrupted international public health efforts. This retrenchment had tangible consequences, such as reduced support for Ebola outbreak response activities in the Democratic Republic of Congo, where aid organizations like the International Rescue Committee curtailed their operations due to decreased U.S. funding. Future plans indicated potential bilateral agreements aimed at scaling down global health programming further, with congressional oversight anticipated to address the impacts of these changes.
Domestically, these policy shifts had direct effects on specific disease control programs. For example, the CDC’s Division of Parasitic Diseases and Malaria was dissolved, and its staff reassigned, interrupting efforts to prevent the reestablishment of malaria in the U.S.. This came amid a 2023 outbreak that infected 10 people across several states, highlighting the vulnerability of the population due to widespread lack of immunity and the presence of mosquito vectors nationwide. While HHS stated that the CDC continues to work with partners to reduce malaria’s burden, the reductions in funding and expertise have raised concerns among health officials and researchers about rising health risks.
Impact on Emerging Disease Surveillance and Response
The Trump administration’s budget cuts to health programs significantly affected the Centers for Disease Control and Prevention’s (CDC) capacity to monitor and respond to emerging infectious diseases. The reduction of approximately 18% of CDC’s full-time workforce, amounting to about 2,400 positions, was accompanied by a strategic refocus on core responsibilities such as infectious disease surveillance, outbreak investigations, and preparedness efforts. However, these cuts also entailed the elimination of roughly $750 million in preparedness grants to states, funds crucial for managing both natural and man-made disasters, including disease outbreaks.
A major concern arising from these funding reductions is the potential weakening of the CDC’s surveillance infrastructure. This system, which includes case tracking, wastewater surveillance, and environmental monitoring, is essential for early detection and containment of infectious diseases. Insufficient funding risks creating critical gaps that could delay identification of outbreaks and hamper timely public health responses. Experts have highlighted that effective disease surveillance relies heavily on real-time data collection and transparent communication, both of which may be compromised by resource constraints.
The administration’s approach also emphasized concentrating global health security efforts on surveillance, data sharing, and laboratory capacity to enable rapid containment of outbreaks, especially those originating outside the United States. To support this goal, the CDC invested in advanced, interoperable data-sharing capabilities designed to provide timely insights to state and local health departments, facilitating trend analysis, disease detection, and preventive measures. Despite these technological advancements, concerns persist that the loss of administrative and research personnel could disrupt laboratory operations and ongoing studies, ultimately impairing the nation’s ability to address emerging threats effectively.
The delayed response to the hantavirus outbreak, where the CDC took nearly a month to establish a response team after the first fatality, underscored the risks associated with diminished preparedness and communication capacity. Public health experts criticized the sluggish reaction and noted that such delays suggest the U.S. may be ill-equipped to handle larger health crises, including future pandemics. This event exemplifies how funding cuts and organizational changes may hinder rapid assessment, risk communication, and mobilization critical to effective outbreak management.
In fiscal year 2026, the CDC pledged to support state, local, and territorial health departments in implementing proven interventions, conducting infectious disease surveillance, and responding to outbreaks with a focus on cost-effective and scalable programs. While these efforts aim to mitigate the impact of funding reductions, the overall effect of the administration’s cuts remains a significant challenge for the country’s emerging disease surveillance and response capacity.
Examples and Case Studies
The Trump administration’s cuts to health programs have had significant repercussions across various infectious disease outbreaks and prevention efforts both domestically and internationally. One notable example is the reduction in funding for the President’s Emergency Plan for AIDS Research (PEPFAR), which supports not only HIV treatment but also millions of HIV tests annually. This has jeopardized surveillance for HIV, impeding the ability to monitor and respond effectively to the epidemic. Epidemiologists warn that this could lead to increased numbers of sick individuals, less efficient healthcare delivery, and wasted resources in managing the disease.
In the United States, the elimination of five CDC HIV prevention branches—including public health communications, behavioral surveillance, and non-laboratory research—has resulted in lost staff, expertise, and the termination of successful initiatives such as the Take Me Home testing program. This undermines efforts to prevent new infections at a time when updated CDC modeling projects a substantial increase in the number of people needing pre-exposure prophylaxis (PrEP) from 1.2 million to 2.2 million, an 83 percent rise.
Emerging and reemerging infectious diseases have also been affected. In 2023, local transmission of malaria was reported in Arkansas, Florida, Maryland, and Texas, with ten people infected. Given that mosquitoes capable of transmitting malaria are widespread throughout much of the country and that most U.S. residents lack protective immunity, the risk of severe illness and death is heightened. Although the Department of Health and Human Services (HHS) declined to comment on specific budget cuts, the CDC continues to collaborate with domestic and international partners to mitigate malaria’s burden and prevent its reestablishment in the U.S..
Similarly, surveillance and outbreak preparedness in global hotspots have been compromised. The International Rescue Committee (IRC) reported that funding reductions forced it to scale back health and preparedness operations in Congo’s Ituri Province from five health zones to two, a region that has since become the epicenter of an Ebola virus outbreak. IRC officials emphasized that these funding cuts have left the area dangerously exposed, with surveillance systems only now beginning to catch up with ongoing transmission that likely started some time ago.
Other infectious diseases such as measles have seen a resurgence within the U.S., with cases reaching a 33-year high of 1,267 reported cases, though the actual number may be higher due to underreporting. This rise underscores the broader vulnerability created by reduced funding and diminished public health infrastructure. Furthermore, outbreaks of diseases typically linked to international travel, such as polio and dengue, continue to pose a threat, highlighting the critical importance of sustained surveillance and prevention efforts.
Organizational and Leadership Changes Within Public Health Agencies
The Trump administration’s restructuring of U.S. global health programs has led to significant organizational changes, though many details remain uncertain. While the reorganization efforts are underway, questions persist regarding which programs will continue and how they will be managed, implemented, and monitored, especially in the context of substantial reductions in federal staffing and healthcare workers affected by funding cuts. Several key leadership roles remain unfilled, including the U.S. Global AIDS Coordinator and the U.S. Malaria Coordinator, both requiring Senate confirmation. The administration’s choices regarding these nominations will influence the direction of global health initiatives.
Within the Centers for Disease Control and Prevention (CDC), the structure comprises multiple centers, offices, and institutes, each with defined leadership roles that oversee specific health priorities and scientific advancements. However, proposals to reorganize parts of the CDC—such as transferring experts in noncommunicable diseases to a new agency—have been criticized for potentially increasing bureaucracy without improving efficiency. Such shifts coincide with broader federal workforce reductions, including an 18% cut at the Food and Drug Administration, amounting to approximately 3,500 lost positions.
These organizational disruptions have broader implications for public health data collection and dissemination. The resulting destruction and disruption of data infrastructure impair the ability of health systems to control costs, maintain quality, and ensure equity by limiting policymakers’ capacity to identify and respond to emerging health challenges. Overall, these leadership and structural changes within public health agencies reflect a significant transformation in how the U.S. manages and prioritizes public health efforts during this period.
Public and Political Reactions
The Trump administration’s proposed budget cuts to public health and biomedical research programs have faced strong opposition from lawmakers, the scientific community, and public health experts. Critics warn that these reductions, particularly targeting agencies like the Centers for Disease Control and Prevention (CDC), could severely undermine the nation’s ability to respond to emerging disease threats and jeopardize public health. The proposed 43% cut to the CDC’s funding in earlier budget proposals, which was later detailed with even deeper spending and staffing reductions, has drawn sharp condemnation from biomedical research proponents. Mary Woolley, President and CEO of Research!America, stated that enacting such cuts would result in Americans becoming “sicker, poorer, and die younger”.
Public health experts have emphasized the heightened risks posed by these budgetary decisions amid expanding pathogen territories driven by climate change. Researchers note that the Trump administration’s decreased investment in programs that prevent, track, and respond to health hazards is a dangerous abdication of federal responsibility in safeguarding the population against infectious diseases. The cuts are also seen as a retreat from America’s historical role of intellectual and technical leadership in global health, which could result in substantial human costs including death, disease, lost economic output, and geopolitical instability.
Beyond the scientific and health communities, policymakers and analysts have highlighted the critical importance of multi-layered public health infrastructure to protect individuals and communities from infectious diseases. Janeen Madan Keller, deputy director of global health policy at the Center for Global Development, stressed that because infectious diseases do not respect borders, maintaining the ability to contain outbreaks globally before they reach the United States is essential.
The administration’s approach has also sparked debate within the Department of Health and Human Services (HHS). While some officials, like Secretary Robert F. Kennedy Jr., have prioritized chronic disease prevention, critics argue this focus comes at the expense of infectious disease control efforts. Health experts like Ashish Jha have criticized this shift as a “bait and switch” that weakens defenses against microbial threats, though HHS representatives dispute this characterization and maintain that the agency is becoming more effective.
Additionally, the Trump administration’s withdrawal from the World Health Organization (WHO) provoked backlash from public health experts, who viewed the move as undermining international cooperation crucial for global disease surveillance and response. Reorganizations within the State Department, such as the restructuring of the Global Health Security Directorate, and executive actions affecting public participation in health-related decision-making have also been scrutinized as part of broader efforts that critics argue diminish the country’s preparedness against emerging health threats.
Comparative Analysis
The Trump administration’s health policy changes, particularly the cuts to global health programs and alterations to the Affordable Care Act (ACA), have significant implications for emerging disease risks and public health outcomes. These policy shifts have been characterized by reductions in funding and modifications
The content is provided by Harper Eastwood, Lifelong Health Tips
